Introduction: Loss of function of BRCA1 associated protein 1 (BAP1) is observed in about 50% of malignant pleural mesothelioma (MPM) cases. The aim of this study was to investigate whether this aspect could be exploited for targeted therapy.
Introduction
Malignant pleura mesothelioma (MPM) is an aggressive cancer deriving from the mesothelium and more frequently occurring in the pleural cavity. Because clinical symptoms only appear with advanced disease, and mesothelioma is characterized by being highly aggressive, the median survival is approximately 8 to 27 months depending on histotype and therapy 1 . Thus, a significant need for new therapeutic approaches is warranted.
In the era of personalized medicine, one strategy is to investigate weaknesses that are dependent on mutated genes, therefore our original intention was to investigate synthetic lethality with mutated BRCA1-associated protein (BAP1). Indeed, BAP1 is the second most mutated gene in MPM (COSMIC, cancer.sanger.ac.uk V85) after CDKN2A (cyclin-dependent kinase inhibitor 2A) and loss of function of BAP1 has been reported in up to 50% of MPM 2 , 3 .
BAP1 belongs to the group of deubiquitinating enzymes whose main function is the removal of ubiquitin entities from different targets, thereby opposing the function of E3 ligases 4 ; 5 ; 6 . BAP1 is found in multiprotein complexes and it takes part in several cellular processes including gene expression regulation 7 . For example, BAP1 dimer is found to form two different complexes with the chromatin binders ASXL1 and ASXL2, human homologs of Drosophila additional sex combs (ASX), which are both able to deubiquitinate histone monoubiquitylated (H2Aub1) 8 ; 9 ; 10 . H2Aub1 is considered to be a key effector in transcriptional repression mediated by polycomb repressor 1 complex in target gene promoters although there are examples where repressive action of PRC1 is independent of H2Aub1 11 . In addition, Bap1 homolog in Drosophila, Calypso, in a complex with ASX named Polycomb repressive deubiquitinase (PR-DUB), is responsible for repression of HOX genes by maintaining H2A deubiquitinated in embryo while increasing HOX expression in particular tissues 8 . Therefore, although H2Aub1 is largely used to monitor BAP1 activity, it has an unclear and fine-tuning role in the control of gene expression. BAP1 binds BRCA1-associated RING domain 1 (BARD), modifies BRCA ubiquitination and BAP1deficient cells are sensitive to ionizing radiation and PARP inhibition 12 ; 13 . In addition, we recently described that in the presence of wild-type BAP1 the expression of an alternative splice isoform of Bap1 (BAP1Δ) missing part of the catalytic domain, sensitizes to PARP inhibition, likely by competing with full length BAP1 for complex formation 14 .
In this study, using a genetically engineered model expressing either functional or non-functional BAP1 in the same genetic background we performed whole-genome siRNA screens assessing impaired survival comparing BAP1-proficient vs. BAP1-deficient MPM cells. Silencing ribonucleotide reductase subunits RRM1 and RRM2 conferred an increased lethality in BAP1proficient cells. This observation was confirmed in a large panel of BAP1-proficient cells, which were more sensitive to ribonucleotide reductase inhibition compared to BAP1-deficient cells and we show that this is linked to a repressor activity of BAP1.
Material & Methods

Reagents
Dulbecco's Modified Eagle's Medium/Nutrient Mixture F12 Ham (DMEM-F12) medium and Penicillin/Streptomycin 100X stock solution were purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). Trypsin-EDTA 0.25% 1X solution and OptiMEM medium were purchased from GIBCO (Life Technologies Europe, Zug, Switzerland). Fetal calf serum (FCS, CVFSVF00-01) was purchased from PAN Biotech (Aidenbach, Germany). Puromycin was obtained from AppliChem (Darmstadt, Germany). Olaparib (AZD2281, Ku-0059436) was purchased from Selleckchem (Houston, TX), gemcitabine was obtained from Lilly (Indianapolis, IN) and hydroxyurea from AppliChem (Darmstadt, Germany).
Cell culture
The human mesothelioma cell lines used in this study were obtained either from ATCC (Wesel, Germany): HEK293, NCI-H226, NCI-H2452, NCI-H2052; or from Riken BRC (Ibaraki, Japan):
ACC-Meso-1 and ACC-Meso-4; or from European Collection of Cell Cultures (Salisbury, UK):
Mero-82. The following cell lines were established in our laboratory: SPC111, ZL55 and were 5 cultured as previously described 15 . HEK293 cells were grown in DMEM supplemented with 10% FCS and 1% Penicillin/Streptomycin. All the other cell lines were maintained in DMEM-F12 supplemented with 15% FCS and 1% Penicillin/Streptomycin solution. Stably transfected cells were selected with puromycin. All cell lines were cultured at 37 °C in a humidified 5% CO 2 incubator.
RNAi screen
High-throughput screening (HTS) was performed as previously described 16 , using established automated liquid handling procedures. Three individual genome-wide screens were performed per cell line. Briefly, the siARRAY Human Genome library (Dharmacon, Thermo Fisher, Scientific, Lafayette, CO) comprising single-target pools of four distinct siRNAs was dispensed into 384-well plates (Greiner, Kremsmunster, Austria) at a concentration of 1.5 pmol in 10 µl 1X siRNA buffer (Dharmacon). siGENOME Non-Targeting control pool#1 and the siGENOME UBB SMARTpool siRNA (Dharmacon) were used as negative and positive control respectively.
Plates were stored at -20°C until use. Then, DharmaFECT 1 transfection reagent (Dharmacon) diluted in OptiMEM (GIBCO) was added to the wells using a Multidrop Combi (Thermo Fisher Scientific) (final concentration of 0.009 µl/well; 0.012%). Within two hours, 500 cells/well in a volume of 55 µl of DMEM-F12 were plated using microFill cell dispenser (BioTek, Winooski, VT) into 384-well plates containing the complexes, resulting in a final siRNA concentration of 20 nM and a final volume of 75 µl. After plating, cells were grown at normal cell culture conditions for 5 days, and then 6 µl of the CellTiter-Blue (Promega, Madison, WI) was added into the wells. After 4 h incubation, 15 µl of 6% SDS was added to stop the reaction and fluorescence was measured (540Ex/590Em).
The potency of the selected hits was validated in deconvolution experiments in non-automated setup: four distinct siRNAs for each gene were tested via viability assay and via western blotting (in order to assess protein knockdown efficiency and correlation with observed lethality) using exactly the same conditions and reagents as described above.
RNAi screen analysis 6
Raw fluorescence data were processed in R. Data were log2-transformed for all the screens and lethality scores were calculated relative to controls on plate according to the equation: lethality score = (median of siRNA x -median of siNonTargeting) / (median siUBB -median siNonTargeting). Quantile normalization of lethality scores was calculated using CellHTS2 R package. Identification of scores significantly different between cell lines was analysed by limma R package.
RNA extraction, cDNA synthesis and q-PCR
0.5 µg of total RNA was extracted from cells using RNeasy isolation kit (Qiagen, Hilden, Germany) and reverse-transcribed using the Quantitect Reverse Transcription Kit (Qiagen). Real-time qPCR was performed using QuantiTect SYBR Green PCR kit (Qiagen) and products were detected on a 7900HT
Fast real-Time PCR system (Applied Biosystems, Thermo Fisher Scientific). Relative mRNA levels were determined by comparing the PCR cycle thresholds between cDNA of a specific gene and histone H3 (ΔCt method) 17 . Primers used for qPCR are listed in Supplementary Table 1 .
Protein extraction and Western Blotting
Total protein extracts were obtained by lysing the cells with hot Laemmli sample buffer (60 mM Tris-Cl pH 6.8, 100 mM DTT, 5% glycerol, 1, 7% SDS) and pressed few times through syringes (26 G) 17 . Spheroids were collected 48 h post-treatment. Protein concentration was determined using a Pierce™660nm Protein Assay (Thermo Fisher Scientific). Core histone extracts were prepared by acidic extraction as previously described 14 and their concentration was determined using Bradford protein assay. Proteins were prepared by adding 6X reducing Laemmli buffer and boiling for 5 min and a total of 5 µg of total protein extracts or 0.5 µg of purified histones were separated on denaturing 10% or 15% SDS-PAGE gels based on the target size and proteins were transferred onto PVDF 
BAP1 cloning, sequencing and transfection
Human BAP1 cDNA amplified from MPM cell lines was subcloned into the EcoRI/NheI site of the pCI-puro vector, which contains a puromycin resistance gene 14 . To obtain specific nonsynonymous mutations within BAP1 gene or synonymous mutations allowing siRNA resistance the QuikChange II Site-Directed Mutagenesis kit (Stratagene, San Diego, CA) was used. All inserts were validated by sequencing and all primers are indicated in Supplementary Table 1 . For isogenic BAP1 cell lines used in the screen NCI-H2452 cells were transfected with pCI-Puro_BAP1_WT (Addgene #68365) using Lipofectamine 2000 reagent (Thermo Fisher Scientific) according to manufacturer's instruction. For further experiments, HEK293T and NCI-H2452 cells were transfected transiently or stably with either control empty vector, pCI-Puro_BAP1_WT (Addgene #108439) or pCI-Puro_BAP1_C91A (Addgene #108438) using the same method of transfection.
RNA interference and drug treatment
In order to down-regulate BAP1 expression, ON-TARGETplus SMARTpool or single siRNAs against BAP1 or siGENOME Non-Targeting siRNA pool #1 as well as DharmaFECT 1 transfection reagent were obtained from Dharmacon. For RRM1 and RRM2 knockdown efficiency validation in MPM cell lines, pools of the two best distinct siRNAs against RRM1 (siRRM1 #3 and #4) and RRM2 (siRRM2 #1 and #3) were used at the same concentration as in the screen. Briefly, siRNA dissolved in 1X siRNA buffer (Dharmacon) was combined with transfection reagent dissolved in OptiMEM (final concentration of 0.42 µl/well per well; 0.042%) and incubated for 20 min. Then, cells resuspended in normal growth medium were added to the siRNA/DharmaFECT 1 mixture and seeded onto plates, allowing for a final siRNA concentration of 20 nM. 0.5 × 10 5 cells (12-well plate) were plated for whole cell protein lysates as wells as RNA extraction. 24 h later, cells were treated with either gemcitabine or hydroxyurea (final concentration of 0.1 µM and 0.2 µM respectively) and 48 h later protein lysates were prepared.
Clonogenic assay
Colony formation assays were performed as follows: NCI-H2452 clonal cells were plated at density of 1000/well in 6-well plate and subjected to treatment with different concentrations of a specific drug after 1 and 5 days. After additional 5 days cells were stained with Crystal Violet and colonies were counted by eye.
Spheroids formation and viability assay
Spheroids formation assays were performed as previously described 18 . At day 4 after seeding the spheroids were treated continuously with the drugs (0.01, 0.1, 1.0, 10.0, 100.0, and 500 µM gemcitabine or 0.1, 0.5, 2.0 mM of hydroxyurea or remained untreated) for 6 days and viability was analyzed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), to determine the ATP content. Luminescence was acquired using GloMax 96 Microplate Luminometer (Promega). Each experiment was performed in triplicate.
Statistical analysis
Fluorescence data from the cell viability screen were log2-transformed, normalized to the negative control (siNon-Targeting) per plate, and synthetic lethality scores were calculated.
Statistical analysis was performed using GraphPad Prism version 5.04. Differences with p <0.05 were considered significant.
Results
Whole-genome RNAi screen reveals genetic vulnerabilities in BAP1 WT cell line
In order to identify genes whose inhibition induces synthetic lethality specifically in BAP1 loss-offunction MPM cells, we generated isogenic BAP1-proficient and BAP-deficient cell lines by stably transfecting NCI-H2452 BAP1 A95D/-5, 19 cell line with either a BAP1 wild-type (BAP1) expression vector or an empty vector (EV). Multiple BAP1-proficient independent clones were generated and characterized by H2Aub1 levels, as well as their response to olaparib in comparison to EV clonal cell lines. The selected BAP1 expressing clone was shown to exhibit similar growth characteristics as an EV clone (data not shown). In addition, BAP1 expression decreased H2Aub1 ( Figure 1A After storage until use, the experiment started by adding transfection reagent and subsequently cells to the plates to allow reverse transfection. After 5 days, viability was measured by reading fluorescence and lethality score and significant hits were evaluated for BAP1-proficient vs -deficient lines ( Supplementary Figure 2 ). Differential lethality was then calculated between the two cell lines ( Figure 1C ). 1775 genes were found to be significantly (p <0.05) different when comparing BAP1proficient vs BAP1-deficient cell line. Consistent with clones' characterization, we observed a difference in lethality score of 0.12 and of 0.08 between BAP1-proficient vs -deficient line for siPARP1 and for siPARP2, respectively. However, effects on viability were poor compared to effects of olaparib, likely because the drug inhibits both enzymes. From the list of 1775 genes we first considered the 191 genes where a differential lethality score ≥0.2 between BAP1-proficient vsdeficient line had been calculated. We searched for functional enrichment by gene ontology analysis using DAVID 20 . Interestingly, using the Functional Annotation Clustering tool, the most enriched functional cluster was a group of terms associated with RNA splicing and processing (enrichment score 4.23; Supplementary Table 2 ), which also had the highest score in a screen for genes involved in the so called replicative stress 21 , which is a term describing replication forks slowing or stalling by endogenously-or exogenously-derived impediments of DNA polymerases 22 . We then took into account only genes with a differential lethality score ≥0.3 and FDR <0.05. The analysis revealed 11 significant differentially lethal genes (Table 1) . Surprisingly, depletion of all the 11 hits were more cytotoxic for BAP1 WT cell line.
BAP1-proficient cells are more sensitive to RRM1 and RRM2 silencing
Two genes out of the 11 hits, namely RRM1 and RRM2, encode the two subunits that together form a protein heterotetramer (containing two copies of the catalytic subunit RRM1 and two copies of the regulatory subunit, RRM2) called ribonucleotide reductase (RNR), a key enzyme in de novo synthesis of dNTPs that converts ribonucleotide diphosphates (NDP) into deoxyribonucleotide diphosphates (dNDP), after which the NDP-kinase (NDPK) catalyzes the conversion of dNDPs to dNTPs 23 . Since RNR is of particular clinical relevance, as a drug targeting this enzyme is already used in second line therapy in mesothelioma, we decided to focus on RRM1 and RRM2 for further characterization. The genome-wide RNAi library comprises pools of four individual siRNAs per gene.
Therefore, we deconvoluted each siRNA pool used in the screen for these 2 hits in order to exclude possible false-positive effects 24 . We investigated the effect of individual siRNAs on overall lethality as well as a BAP1-dependent lethality. Viability assays were performed with four individual siRNAs targeting either RRM1 (siRRM1 #1, #2, #3, #4) or RRM2 (siRRM2 #1, #2, #3, #4) ( Figure 2A ).
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Efficiency of RRM1 and RRM2 knockdown demonstrated that best knockdown was obtained with RRM1 #3 and #4 and RRM2 #1 and #3 (Supplementary Figure 3A and B) . Moreover, as observed previously in the original screens, the BAP1 WT expressing clonal cell line was significantly more sensitive to RRM1 or RRM2 depletion compared to the EV clonal cell line (Figure 2A ).
We then aimed at verifying the effect of RRM1 or RRM2 depletion in a broader panel of malignant pleural mesothelioma (MPM) cell lines. Four cell lines representing BAP1 wild-type group (BAP1 WT) (SPC111, ACC-Meso-1, NCI-H2052 and Mero82) 14 and three BAP1 mutated or deleted (mut/del) cell lines (NCI-H226 25 , NCI-H2452, ACC-Meso-4 26 ) were transfected with a pool of the two siRNAs targeting RRM1 or RRM2 mentioned above, and the efficiency of the knockdown in all cell lines was assessed ( Supplementary Figure 4A and B) . Interestingly we noticed that silencing either RRM1 or RRM2 upregulates the expression of the other subunit (Supplementary Figure 4A and B) in all cell lines, consistent with a reciprocal co-regulation 27 . We then assessed viability upon silencing. MPM cell lines expressing BAP1 WT demonstrated lower surviving fraction upon RRM1 and RRM2 knockdown compared to cells with BAP1 mut/del status ( Figure 2B ), suggesting higher sensitivity to siRNA-mediated depletion of RRM1 and RRM2. Noteworthy, expression of RRM1 as well as RRM2 was generally lower in BAP1 WT positive MPM cell lines on both mRNA and protein level compared to the BAP1 mut/del MPM cell lines (Supplementary Figure 5A and B), although this was not particularly associated with different growth rates. Publicly available TCGA mRNA expression data of 87 MPM samples (MESO) revealed that a similar inverse relationship between BAP1 and RRM1 or RRM2 exists as well in clinical samples (Supplementary Figure 6) .
Overall, these data provide evidence that sensitivity of MPM cells to RRM1 or RRM2 depletion might depend on BAP1 status, BAP1 WT cell lines being more vulnerable.
BAP1 WT MPM cell lines are more sensitive to gemcitabine and hydroxyurea
As there are known selective inhibitors against RRM1 and RRM2 already used in clinics, namely gemcitabine and hydroxyurea, respectively, we aimed to test their effect on growth on a panel of MPM cell lines. For that reason, BAP1 WT and BAP1 mut/del cell lines were grown in spheroids to better mimic in vivo conditions 18 and subsequently treated with increasing concentrations of gemcitabine (0.01, 0.1, 1.0, 10, 100, 500 µM) or hydroxyurea (0.1, 0.5, 2.0 mM). Consistent with the effect of RRM1i, gemcitabine was approximately thousand fold more potent in decreasing the viability in the BAP1 WT group (Figure 3A and C) . A similar effect was observed in spheroids treated with hydroxyurea, where the most evident separation in lethality between the two groups was detected at the concentration of 2 mM ( Figure 3B and C) .
Taken together, these data provide evidence and confirmation of the previous findings based on siRNA interference, that BAP1 WT positive MPM cells are more sensitive to RRM1 and RRM2 inhibition.
Expression of BAP1 sensitizes NCI-2452 cells to RNR inhibition
In order to understand whether decreased expression of RRM1 and RRM2 observed in 2D conditions was maintained in 3D, thereby potentially underlying the differential sensitivity to RNR inhibition, we assessed RRM1 and RRM2 expression in baseline and upon drug treatment.
Since the previous experiments revealed certain vulnerabilities in BAP1 WT MPM cell lines, we decided to investigate whether BAP1 was an underlying genetic factor determining this susceptibility.
Contrarily to the observation in 2D, in 3D there was no obvious differential expression of RRM1 and RRM2 between BAP1 WT and BAP1 mut/del group under basal conditions ( Figure 4A ). In addition, we observed no clear differential pattern in RRM1 expression upon treatment ( Figure 4A Although we did not measure cellular dNTP pools and previous studies showed no dNTP depletion upon hydroxyurea in mammalian cells 29 , we assume that gemcitabine caused nucleotide depletion because supplementation of dNMP rescued its toxicity (data not shown). Decreasing the deoxynucleotide pool leads to slowing or stalling of the replication forks and loss of polymerase 13 processivity leading to formation of a tract of single stranded DNA causing genetic instability resulting in H2AX phosphorylation [30] [31] [32] . Therefore, we tested expression of ƴH2AX, as well as pKAP1, two down-stream targets of ATM, and therefore being indicative of replicative stress. ƴH2AX levels were higher in the treated samples ( Figure 4B) . Similarly, pKAP1 levels were up-regulated upon both gemcitabine and hydroxyurea treatment. P53 was phosphorylated and stabilized upon gemcitabine and hydroxyurea treatment, indicating replicative stress in concordance with ƴH2AX levels ( Figure 4C ). We observed no p53 signal in NCI-H2452 cell line, which has a mutation inducing a truncated p53 33 , and very low levels in ACC-Meso-1 and ACC-Meso-4, which have WT p53 34 .
Since BAP1 is phosphorylated in an ATM-dependent manner at S592 35, 36 , we tested whether gemcitabine or hydroxyurea treatment had an impact on BAP1 S592 phosphorylation. As expected, pBAP1 was detectable in all BAP1 WT cell lines samples upon the treatments ( Figure 4B ).
Noteworthy, although the pBAP1 fraction was clearly elevated upon the treatment compared to the untreated cells, the total BAP1 level diminished in both gemcitabine and hydroxyurea treated BAP1 WT spheroids.
Altogether, this data suggests that although DNA damage signalling was activated in both BAP1proficient and -deficient cells, BAP1 mut/del cell lines are characterized by higher up-regulation of RRM2 upon a treatment, which suggests a possible resistance mechanism of BAP1 mut/del cell lines to gemcitabine and hydroxyurea.
Sensitization of MPM cells to gemcitabine and hydroxyurea is dependent on deubiquitinating activity of BAP1
In order to exclude the possibility of the interplay of the diverse genetic backgrounds in all tested cell lines, we generated de novo NCI-H2452 cell line stably transfected with either EV, or BAP1 WT or a BAP1 C91A, a previously described catalytic dead mutant (C91A) 25, 37 . Then, we monitored BAP1 expression at protein level (Supplementary Figure 7A) as well as deubiquitinating (DUB) activity of the two variants. Interestingly, endogenous mutated BAP1 is phosphorylated under basal 2D conditions, contrarily to what we had observed in basal conditions in 3D (see Figure 4B ). HEK293 cells transiently transfected with BAP1 WT show diminished levels of H2Aub1, in contrast to C91A mutant (Supplementary Figure 7B ) consistent with what has been previously reported 8, 25, 37 .
Subsequently, we tested the viability of the cells grown in spheroids upon gemcitabine or hydroxyurea treatment.
As expected, cells expressing BAP1 WT, but not C91A mutant, are sensitized to gemcitabine compared to cells transfected with EV ( Figure 5A ). The same observation was made for cells treated with hydroxyurea ( Figure 5B) . These results suggest that BAP1 DUB activity plays a crucial role in the mechanism of the observed sensitization.
BAP1 regulates RRM2 up-regulation in replication stress
To further investigate mechanisms underlying BAP1 effects on sensitization to gemcitabine and hydroxyurea we tested whether BAP1 WT reconstitution in NCI-H2452 cells would rescue these cells from high RRM2 up-regulation. NCI-H2452 cell lines stably expressing either EV, or BAP1 WT or C91A mutant were grown in 3D and treated with gemcitabine or hydroxyurea for 48 h. NCI-H2452 cell line reconstituted with BAP1 WT but not C91A mutant, showed a decreased induction of RRM2 expression compared to EV-transfected cells upon the treatments ( Figure 6A ). Conversely, silencing BAP1 in SPC111 cells expressing BAP1 WT resulted in a significant increased expression of RRM2 on protein as well as on mRNA level upon treatment of the cells with gemcitabine or hydroxyurea ( Figure 6B ). DNA upregulates RRM2 at least partially via upregulation of E2F1 transcription factor 38 , therefore we investigated expression of the latter and observed indeed increased levels of E2F1 upon drug treatment in BAP1 knocked down cells.
As we had observed in 3D, drug treatment led to a decrease of BAP1 protein, but levels of mRNA were not affected ( Figure 6B ).
Altogether, these data provide further evidence that BAP1 mut/del cells react to replication stressinducing agents with higher RRM2 up-regulation compared to BAP1 WT cells, suggesting an involvement of BAP1 WT in modulating E2F1 and RRM2 increase in replicative stress conditions ( Supplementary Figure 8 ).
Discussion
In this study we describe that BAP1 loss induces chemoresistance to drugs inhibiting RNR in mesothelioma cells and this observation has immediate clinical implications since gemcitabine is used in second line mesothelioma treatment 39 .
Differential synthetic lethality between BAP1-proficient vs. -deficient cells included the RNR subunits RRM1 and RRM2 and we concentrated on understanding the underlying mechanisms because of the translational importance of this observation. RNR activity is necessary for DNA replication and repair.
The activity of this enzyme is controlled at the transcriptional level during the cell cycle with maximal levels during S-phase. While levels of RRM1 protein are almost constant in proliferating cells owing to a long half-life, the RRM2 protein is specifically degraded in late mitosis after polyubiquitination by the anaphase-promoting complex-Cdh1 ubiquitin ligase (reviewed in 40 ).
It has been estimated that in 3D spheroids about one third of the cells are in quiescent state 41 , corresponding better to the proliferation status of tumoral cells 42 compared to 2D cell culture.
Therefore, in this model there are proliferating cells and non-proliferating cells, which could be less sensitive to the lack of deoxynucleotides. Nevertheless, using this system we observed more than 3 log differences for the IC50 between BAP1-proficient and -deficient cells. Quiescent cells still need deoxynucleotides for DNA repair and mitochondrial DNA synthesis, and a certain threshold concentration is necessary for some repair DNA polymerases (reviewed in 40 ). Therefore, cells also express an alternative subunit having the same properties as RRM2, i.e., RR2B, which allows cells to produce enough deoxynucleotides in the absence of RRM2 29 . However, levels of RR2B were very low even in the 3D model under conditions of RRM1 and RRM2 inhibition (data not shown), excluding any compensatory role for RR2B under our experimental conditions. Consistent with a previous study where silencing RRM1 and RRM2 caused genomic instability detectable through phosphorylation of histone variant H2AX 21 , we observed activation of ATM in spheroids upon gemcitabine and hydroxyurea treatment. As expected, this led also to BAP1 phosphorylation since BAP1 is phosphorylated upon DNA damage on ATM and ATR consensus sites 36, 43 . Ionizing radiation (IR) or hydroxyurea result in rapid phosphorylation of a small fraction of BAP1 at S592 in S-phase and dissociation from chromatin, to presumably regulate expression of DNA damage repair genes 35 . In parallel to BAP1 phosphorylation we observed a decrease of BAP1 protein levels, consistent with a previous study where Bap1 levels decreased after IR 44 . Upon gemcitabine and hydroxyurea treatment we could not detect any significant downregulation of BAP1 mRNA, while BAP1 protein levels were maintained in cells transfected with a WT BAP1 expression plasmid (data not shown). Therefore, we hypothesize that downregulation of BAP1 under conditions of genomic instability occurs at a post-transcriptional level, possibly by targeting the BAP1 3'UTR, which could be further investigated.
We observed a repressor role for BAP1 on the expression of RRM2 upon the response to inhibition of RNR, when RRM1 and RRM2 are upregulated. It is likely that the identification of RRM1 and RRM2 as BAP1 synthetic lethal targets in the screen, which was performed in the absence of any exogenously induced replicative stress, was due to the serendipitous choice of the model, where we sought differences between BAP1-proficient vs.-deficient cells in transfected cells that undergo replicative stress and BAP1 phosphorylation when grown in 2D.
Upregulation of RRM1 and RRM2 is consistent with various studies showing that DNA damaging agents increase the levels of RNR subunits 38, 45, 46 . In mammalian cells, upregulation of RRM2 after exposure of the cells to HU has been linked to decreased binding of RFX repressor to RRM2 promoter 47 . Therefore a possible scenario is that RFX is more freely released in the absence of BAP1. Although RFX is not among previously reported BAP1 interactors 48 , it might have been missed because this wide interactome study had been performed in the absence of replicative stress.
Another possibility is that BAP1 interacts with positive regulators of RRM2. RRM1 and RRM2 are part of the genes upregulated in Retinoblastoma (Rb) deficient mouse embryo fibroblast 49 .
Rb negatively controls the activity of E2F transcription factors, therefore regulators of E2F transcription factors can affect RRM1 and RRM2 expression. Genotoxic stress upregulates RRM2 at least partially via upregulation of E2F1 38 . The latter is stabilized downstream of ATM activity 50 and we also observed increased levels of E2F1 upon silencing of BAP1 in replicative stress condition. E2F1 is regulated by post-translational modifications during the cell cycle progression and in response to DNA damage (reviewed 51 ) including by K63 ubiquitination 52, 53 and UCH37, a member of the same DUB family as BAP1, has been shown to increase E2F1 activity 52 . In addition, BAP1 is known to bind Host Cell factor 1 (HCF-1) and the latter recruits activating methyltransferases to E2Fresponsive promoters resulting in transcriptional activation of cell-cycle specific genes 54 . However, although BAP1 deubiquitinates HCF-1 on K48-linked ubiquitin chains 55, 56 , differential gene expression revealed a significant BAP1-dependent effect on RRM1 but not RRM2 upregulation 57 . This is in contrast to the inverse relationship that we have observed, however, BAP1 is a complex protein acting as gene expression activator or repressor depending on the context. Even within the Finally, BRCA1 acts as a transcriptional co-activator of RRM2 59 , so BAP1 effects could be mediated by its interaction with BRCA1. However, as this mechanism of RRM2 regulation could be observed in glioblastoma cells but not in other cancer cell type, it is less likely. BAP1 suppression of RRM2 expression upon replicative stress is consistent with tumor suppressor activity of BAP1 since overexpression of RRM2 is mutagenic in mouse cells and promotes lung carcinogenesis 60 . Interestingly, high levels of RRM1 and RRM2 expression are associated with worst overall survival in MPM patients ( Supplementary Figure 9 ) and it would be of interest to investigate whether this is associated with BAP1 status. BAP1 could be part of the tightly regulated mechanisms to keep RRM2 expression under control since BAP1 is downregulated and phosphorylated upon replicative stress and phosphorylation has been linked to dissociation from chromatin (see above).
As previously mentioned, gemcitabine is already part of second line treatment of MPM patients and the investigation of response according to BAP1 status will be assessed in current clinical trials (NCT02991482, EORTC-NAVALT19) to verify whether BAP1 status is a predictor of response to this therapy. 
